Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
FDA approves colchicine for CVD | Top 20 children’s hospitals | Heart damage after TAVR | More from the last week
Saturday, June 24, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

This Week’s News

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

READ MORE >
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
READ MORE >

Cardiologist kills himself after starting antibiotic, prompting coroner to share concerns

The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist kills himself after starting antibiotic, prompting coroner to share concerns

Share on Twitter Share on Facebook Share on Linkedin
The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. 
READ MORE >

FDA approves next-gen DCB, earning the manufacturer a $27M payment from Abbott

The new-look DCB was designed to provide care with a significantly lower drug load than similar devices. 

READ MORE >
The Surmodics SurVeil drug-coated balloon to treat peripheral artery disease.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves next-gen DCB, earning the manufacturer a $27M payment from Abbott

Share on Twitter Share on Facebook Share on Linkedin
The Surmodics SurVeil drug-coated balloon to treat peripheral artery disease.
The new-look DCB was designed to provide care with a significantly lower drug load than similar devices. 
READ MORE >

Top 20 children’s hospitals for cardiology and heart surgery

Did your facility make the cut? For its 2023-2024 list, U.S. News and World Report evaluated data from 119 hospitals and surveyed thousands of pediatric specialists.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Top 20 children’s hospitals for cardiology and heart surgery

Share on Twitter Share on Facebook Share on Linkedin
Did your facility make the cut? For its 2023-2024 list, U.S. News and World Report evaluated data from 119 hospitals and surveyed thousands of pediatric specialists.
READ MORE >

Heart damage after TAVR: Follow-up imaging helps cardiologists anticipate problems

While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others. 

READ MORE >
A TAVR procedure being performed at Northwestern Medicine in Chicago.
Share on Twitter Share on Facebook Share on Linkedin

Heart damage after TAVR: Follow-up imaging helps cardiologists anticipate problems

Share on Twitter Share on Facebook Share on Linkedin
A TAVR procedure being performed at Northwestern Medicine in Chicago.
While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others. 
READ MORE >

Cardiology group hit by cyberattack, exposing data of nearly 182,000 patients

Patient names, addresses, social security numbers and even medical histories were exposed as a result of the attack, which went unnoticed for more than two months. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Cardiology group hit by cyberattack, exposing data of nearly 182,000 patients

Share on Twitter Share on Facebook Share on Linkedin
Patient names, addresses, social security numbers and even medical histories were exposed as a result of the attack, which went unnoticed for more than two months. 
READ MORE >

FDA clears first ablation catheter with flexible electrode tip, contact force sensing

Contact force-sensing catheters were developed to help overcome the issue of incomplete ablation lesions.

READ MORE >
Abbott's TactiFlex flexible tip, force sensing ablation catheter (right), and its integration with the EnSite X EP mapping system (left) showing the distance from the last ablation. and the contact force during an AFib pulmonary vein isolation.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears first ablation catheter with flexible electrode tip, contact force sensing

Share on Twitter Share on Facebook Share on Linkedin
Abbott's TactiFlex flexible tip, force sensing ablation catheter (right), and its integration with the EnSite X EP mapping system (left) showing the distance from the last ablation. and the contact force during an AFib pulmonary vein isolation.
Contact force-sensing catheters were developed to help overcome the issue of incomplete ablation lesions.
READ MORE >

‘Notably high’ rates of PTSD, depression and anxiety seen in patients with implantable heart devices

"Psychologists have had little involvement in the care of cardiac patients but this needs to change," one researcher said in a statement. 

READ MORE >
‘Notably high’ rates of PTSD, depression and anxiety seen in patients with implantable heart devices
Share on Twitter Share on Facebook Share on Linkedin

‘Notably high’ rates of PTSD, depression and anxiety seen in patients with implantable heart devices

Share on Twitter Share on Facebook Share on Linkedin
‘Notably high’ rates of PTSD, depression and anxiety seen in patients with implantable heart devices
"Psychologists have had little involvement in the care of cardiac patients but this needs to change," one researcher said in a statement. 
READ MORE >

FDA panel to review renal denervation system PMA submissions

The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.

READ MORE >
The ReCor (left) and Medtronic Symplicity Spyral renal denervation systems.
Share on Twitter Share on Facebook Share on Linkedin

FDA panel to review renal denervation system PMA submissions

Share on Twitter Share on Facebook Share on Linkedin
The ReCor (left) and Medtronic Symplicity Spyral renal denervation systems.
The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.
READ MORE >

FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results

Anumana, Pfizer and Mayo Clinic all worked together to develop the advanced algorithm. The groups are now targeting full regulatory approval in the U.S., Europe and Japan.

READ MORE >
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Share on Twitter Share on Facebook Share on Linkedin

FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Anumana, Pfizer and Mayo Clinic all worked together to develop the advanced algorithm. The groups are now targeting full regulatory approval in the U.S., Europe and Japan.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup